Rapt sees share price halve after FDA shelves immunology drug

Rapt Therapeutics had hoped that its immunology drug Zelnecirnon still had a future despite a clinical pause, but recent feedback from the FDA has convinced the biotech company Rapt Therapeutics had hoped that its immunology drug Zelnecirnon still had a future despite a clinical pause, but this Recent feedback from the FDA has convinced the biotech company to abandon the program.